Condition (MeSH)
Hemangioma, Cavernous, Central Nervous System
ClinicalTrials.gov lists 15 trials for Hemangioma, Cavernous, Central Nervous System or a narrower condition beneath it. Recursion Pharmaceuticals Inc. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
15 of the 15 trials are tagged with Hemangioma, Cavernous, Central Nervous System itself; the rest are tagged with a narrower condition beneath it.
When did Hemangioma, Cavernous, Central Nervous System trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 5 |
| 2016 | 1 |
| 2012 | 1 |
| 2010 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemangioma, Cavernous, Central Nervous System trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Not applicable | 1 |
| Observational | 8 |
How many Hemangioma, Cavernous, Central Nervous System trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 5 |
| Terminated | 4 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemangioma, Cavernous, Central Nervous System trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Recursion Pharmaceuticals Inc. | 1 |
Which drugs are being tested for Hemangioma, Cavernous, Central Nervous System? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| ATORVASTATIN | 1 |
| SIMVASTATIN | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Propranolol PO | 2 |
| REC-994 | 1 |
| Observational | 1 |
| Daratumumab SC | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hemangioma, Cavernous, Central Nervous System trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Elevated creatine kinase (CK) | 1 | 1 |
| Fall | 1 | 1 |
Which publications cover Hemangioma, Cavernous, Central Nervous System? (49)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Metformin limits cerebral cavernous malformation development by targeting KLF4-mediated mitochondrial damage. | Biochemical and biophysical research communications | 2025 | Yes |
| Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial. | The Lancet. Neurology | 2025 | Yes |
| Plasma biomarkers in patients with familial cavernous malformation and their first-degree relatives: a cross-sectional study. | Scientific reports | 2025 | Yes |
| Identifying features of prior hemorrhage in cerebral cavernous malformations on quantitative susceptibility maps: a machine learning pilot study. | Journal of neurosurgery | 2025 | Yes |
| Venous Architecture Predicts Hemorrhage Risk in Sporadic CCM With DVA. | Stroke | 2025 | Yes |
Showing 5 of 49 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.